Company / PP&E (Net)
Vaxcyte, Inc. PP&E (Net) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$257.4M
FY2025
5-year range
$8.0M / $257.4M
FY2021-FY2025
Trend
+30.0%
vs FY2024
Sector context
#27 of 193
Health Care
What the data says
Vaxcyte, Inc.'s pp&e (net) of $257M is higher than 86% of companies in the Health Care sector (FY2025). PP&E (Net) has increased for 5 consecutive years, from $3M in FY2020 to $257M in FY2025.
Based on SEC 10-K filings.
$257M in FY2025 with a 5-year CAGR of +139.4%. Top quartile in the Health Care sector.
Improved from $80M to $257M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +191.8%
- 5-Year CAGR
- +139.4%
- 10-Year CAGR
- -
Sector benchmark
Top 14% in Health CareTop 14% of 193This company $257.4M Sector average $777.6M
▼
-66.9% below sector average
Key checks
Key Insights
- Vaxcyte, Inc.'s pp&e (net) has grown for 5 consecutive years.
- 5-year CAGR of +139.4%, indicating consistent growth.
- In FY2025, pp&e (net) increased 30.0% year-over-year.
- Ranks #27 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.94 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $257.4M | +30.0% |
| FY2024 | $198.0M | +148.7% |
| FY2023 | $79.6M | +668.6% |
| FY2022 | $10.4M | +30.2% |
| FY2021 | $8.0M | +143.1% |
| FY2020 | $3.3M | -3.5% |
| FY2019 | $3.4M | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026